Ampersand Biomedicines
Xiying Qu is a seasoned scientist with extensive experience in pharmacology, molecular biology, and cancer therapy. Currently serving as Principal Scientist at Ampersand Biomedicines since October 2021, Xiying leads the in vivo team to assess the efficacy of antibody candidates and explore their mechanisms of action. Previous positions include Senior Scientist at E25Bio, where innovative technologies for detecting viral diseases were developed, and Instructor at Massachusetts General Hospital, focusing on mGluRs as cancer therapy targets. Earlier research involved evaluating HIV dynamics in postdoctoral roles at the University of Pittsburgh and Fudan University, as well as contributions to cancer therapy targets during a PhD and lecturer roles. Xiying holds a Ph.D. in clinical diagnosis of Laboratory Science from Wuhan University, a Master's in Biochemistry and Molecular Biology from Guangdong Medical University, and a Bachelor's in Biotechnology from Ludong University.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.